5 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio

4. Inhibrx, Inc. (NASDAQ:INBX)

Tybourne Capital Management’s Stake Value: $34.2 million

Inhibrx, Inc. (NASDAQ:INBX) is a clinical-stage biotechnology company that is focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. The company also utilizes diverse methods of protein engineering to address the specific requirements of complex targets and disease biology. 

Tybourne Capital Management owns a $34.2 million position in INBX as of the end of the third quarter.